The role of fMRI in drug discovery

Journal of Magnetic Resonance Imaging

Volumn 23, Issue 6, 2006, Pages 862-876

  Wise, Richard G ^a   Tracey, Irene ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Biomarker; BOLD; Drug discovery; fMRI; Neurovascular coupling

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE; DOPAMINE RECEPTOR STIMULATING AGENT; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NICOTINE; REMIFENTANIL; RISPERIDONE; SEROTONIN 3 ANTAGONIST; SEROTONIN TRANSPORTER; SULPIRIDE; TROPISETRON;

BLOOD OXYGENATION; BLOOD OXYGENATION LEVEL DEPENDENT CONTRAST; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM; CIGARETTE SMOKING; DRUG EFFECT; DRUG INDUSTRY; ELECTROENCEPHALOGRAM; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MENTAL DISEASE; NEUROIMAGING; NEUROPHARMACOLOGY; NEUROSCIENCE; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SIGNAL NOISE RATIO; TASK PERFORMANCE; TOBACCO DEPENDENCE;

ANIMALS; BRAIN; BRAIN MAPPING; CLINICAL MEDICINE; DRUG DESIGN; DRUG EVALUATION; EVOKED POTENTIALS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING;

EID: 33744767131     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.20584     Document Type: Review

References (101)

1. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys J 1994;66:259-267.
2. Behrens TE, Johansen-Berg H, Woolrich MW, et al. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci 2003;6:750-757.
3. Conturo TE, Lori NF, Cull TS, et al. Tracking neuronal fiber pathways in the living human brain. Proc Natl Acad Sci USA 1999;96:10422-10427.
4. Heinke W, Schwarzbauer C. In vivo imaging of anaesthetic action in humans: approaches with positron emission tomography (PET) and functional magnetic resonance imaging (fMRI). Br J Anaesth 2002;89:112-122.
5. Heinke W, Fiebach CJ, Schwarzbauer C, Meyer M, Olthoff D, Alter K. Sequential effects of propofol on functional brain activation induced by auditory language processing: an event-related functional magnetic resonance imaging study. Br J Anaesth 2004;92:641-650.
6. Borsook D, Ploghaus A, Becerra L. Utilizing brain imaging for analgesic drug development. Curr Opin Investig Drugs 2002;3:1342-1347.
7. Ploghaus A, Tracey I, Gati JS, et al. Dissociating pain from its anticipation in the human brain. Science 1999;284:1979-1981.
8. Wise RG, Bulte D, Chiarelli P, et al. Towards the measurement of relative CBV using BOLD contrast and mild hypoxia. In: Proceedings of the 13th Annual Meeting of ISMRM, Miami Beach, FL, USA, 2005. (abstract 1491).
9. Lesko LJ, Atkinson AJ, Jr. Use of biomarkers and surrogate end-points in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001;41:347-366.
10. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
11. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003;2:566-580.
12. Rolan P, Atkinson AJ Jr, Lesko LJ. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther 2003;73:284-291.
13. Kalin NH, Davidson RJ, Irwin W, et al. Functional magnetic resonance imaging studies of emotional processing in normal and depressed patients: effects of venlafaxine. J Clin Psychiatry 1997;58 Suppl 16:32-39.
14. Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003;160:64-75.
15. Wise RG, Rogers R, Painter D, et al. Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. Neuroimage 2002;16:999-1014.
16. de Visser SJ, van der Post JP, et al. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 2003;55:39-50.
17. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neurophysiologlcal investigation of the basis of the fMRI signal. Nature 2001;412:150-157.
18. Arthurs OJ, Boniface S. How well do we understand the neural origins of the fMRI BOLD signal? Trends Neurosci 2002;25:27-31.
19. Logothetis NK, Pfeuffer J. On the nature of the BOLD fMRI contrast mechanism. Magn Reson Imaging 2004;22:1517-1531.
20. Logothetis NK, Wandell BA. Interpreting the BOLD signal. Annu Rev Physiol 2004;66:735-769.
21. Breiter HC, Gollub RL, Weisskoff RM, et al. Acute effects of cocaine on human brain activity and emotion. Neuron 1997;19:591-611.
22. Wang J, Aguirre GK, Kimberg DY, Roc AC, Li L, Detre JA. Arterial spin labeling perfusion fMRI with very low task frequency. Magn Reson Med 2003;49:796-802.
23. Bloom AS, Hoffmann RG, Fuller SA, Pankiewicz J, Harsch HH, Stein EA. Determination of drug-induced changes in functional MRI signal using a pharmacokinetic model. Hum Brain Mapp 1999;8:235-244.
24. Stein EA, Pankiewicz J, Harsch HH, et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry 1998;155:1009-1015.
25. Vollm BA, de Araujo IE, Cowen PJ, et al. Methamphetamine activates reward circuitry in drug naive human subjects. Neuropsychopharmacology 2004;29:1715-1722.
26. Austin VC, Blamire AM, Grieve SM, et al. Differences in the BOLD fMRI response to direct and indirect cortical stimulation in the rat. Magn Reson Med 2003;49:838-847.
27. Austin VC, Blamire AM, Allers KA, et al. Confounding effects of anesthesia on functional activation in rodent brain: a study of halothane and alpha-chloralose anesthesia. Neuroimage 2005;24:92-100.
28. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 1999;96:13432-13437.
29. Griffiths PD, Gaines P, Cleveland T, Beard J, Venables G, Wilkinson ID. Assessment of cerebral haemodynamics and vascular reserve In patients with symptomatic carotid artery occlusion: an integrated MR method. Neuroradiology 2005;47:175-182.
30. Tracey I. Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J Clin Pharmacol 2001;Suppl:21S-28S.
31. Rogers R, Wise RG, Painter DJ, Longe SE, Tracey I. An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging. Anesthesiology 2004;100:292-301.
32. Steward CA, Marsden CA, Prior MJ, Morris PG, Shah YB. Methodological considerations in rat brain BOLD contrast pharmacological MRI. Psychopharmacology (Berl) 2005;180:687-704.
33. Febo M, Segarra AC, Tenney JR, Brevard ME, Duong TQ, Ferris CF. Imaging cocaine-induced changes in the mesocorticolimbic dopaminergic system of conscious rats. J Neurosci Methods 2004;139:167-176.
34. Febo M, Segarra AC, Nair G, Schmidt K, Duong TQ, Ferris CF. The neural consequences of repeated cocaine exposure revealed by functional MRI in awake rats. Neuropsychopharmacology 2005;30:936-943.
35. Anderson IM, Clark L, Elliott R, Kulkarni B, Williams SR, Deakin JF. 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport 2002;13:1547-1551.
36. Houston GC, Papadakis NG, Carpenter TA, et al. Mapping of brain activation in response to pharmacological agents using fMRI in the rat. Magn Reson Imaging 2001;19:905-919.
37. Borras MC, Becerra L, Ploghaus A, et al. fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers. J Neurophysiol 2004;91:2723-2733.
38. Lowe AS, Williams SC, Symms MR, Stolerman IP, Shoaib M. Functional magnetic resonance neuroimaging of drug dependence: naloxone-precipitated morphine withdrawal. Neuroimage 2002;17:902-910.
39. Smith SM. Overview of fMRI analysis. In: Jezzard P, Matthews PM, Smith SM, editors. Functional MRI: an introduction to methods, 1st edition. Oxford: Oxford University Press; 2001. p 213-228.
40. Worsley KJ. Statistical analysis of activation images. In: Jezzard P, Matthews PM, Smith SM, editors. Functional MRI: an introduction to methods, 1st edition. Oxford: Oxford University Press; 2001. p 251-270.
41. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(Suppl 1):S208-S219.
42. Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage 2004;21:1732-1747.
43. Beckmann CF, Jenkinson M, Smith SM. General multilevel linear modeling for group analysis in FMRI. Neuroimage 2003;20:1052-1063.
44. Peyron R, Laurent B, Garcia-Larrea L. Functional imaging of brain responses to pain. A review and meta-analysis. Neurophysiol Clin 2000;30:263-288.
45. Cohen MS, DuBois RM. Stability, repeatability, and the expression of signal magnitude in functional magnetic resonance imaging. J Magn Reson Imaging 1999;10:33-40.
46. Aguirre GK, Detre JA, Zarahn E, Alsop DC. Experimental design and the relative sensitivity of BOLD and perfusion fMRI. Neuroimage 2002;15:488-500.
47. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 1999;354:1155-1163.
48. Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science 1999;283:496-497.
49. Attwell D, Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci 2002;25:621-625.
50. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004;5:347-360.
51. Kalisch R, Elbel GK, Gossl C, Czisch M, Auer DP. Blood pressure changes induced by arterial blood withdrawal influence bold signal in anesthetized rats at 7 Tesla: implications for pharmacologic MRI. Neuroimage 2001;14:891-898.
52. Buxton RB, Uludag K, Dubowitz DJ, Liu TT. Modeling the hemodynamic response to brain activation. Neuroimage 2004;23(Suppl 1):S220-S233.
53. Posse S, Kemna LJ, Elghahwagi B, Wiese S, Kiselev VG. Effect of graded hypo- and hypercapnia on fMRI contrast in visual cortex: quantification of T(*)(2) changes by multiecho EPI. Magn Reson Med 2001;46:264-271.
54. Kemna LJ, Posse S. Effect of respiratory CO(2) changes on the temporal dynamics of the hemodynamic response in functional MR imaging. Neuroimage 2001;14:642-649.
55. Corfield DR, Murphy K, Josephs O, Adams L, Turner R. Does hypercapnia-induced cerebral vasodilation modulate the hemodynamic response to neural activation? Neuroimage 2001;13:1207-1211.
56. Hoge RD, Atkinson J, Gill B, Crelier GR, Marrett S, Pike GB. Investigation of BOLD signal dependence on cerebral blood flow and oxygen consumption: the deoxyhemoglobin dilution model. Magn Reson Med 1999;42:849-863.
57. Li TQ, Moseley ME, Glover G. A FAIR study of motor cortex activation under normo- and hypercapnia induced by breath challenge. Neuroimage 1999;10:562-569.
58. Li TQ, Kastrup A, Moseley ME, Glover GH. Changes in baseline cerebral blood flow in humans do not influence regional cerebral blood flow response to photic stimulation. J Magn Reson Imaging 2000;12:757-762.
59. Bandettini PA, Wong EC. A hypercapnia-based normalization method for improved spatial localization of human brain activation with fMRI. NMR Biomed 1997;10:197-203.
60. Cohen ER, Ugurbil K, Kim SG. Effect of basal conditions on the magnitude and dynamics of the blood oxygenation level-dependent fMRI response. J Cereb Blood Flow Metab 2002;22:1042-1053.
61. Brown GG, Eyler Zorrilla LT, Georgy B, Kindermann SS, Wong EC, Buxton RB. BOLD and perfusion response to finger-thumb apposition after acetazolamide administration: differential relationship to global perfusion. J Cereb Blood Flow Metab 2003;23:829-837.
62. Kemna LJ, Kiselev VG, Posse S. Changes of the HRF during hypoxia and hyperoxia measured with event-related BOLD contrast fMRI. Neuroimage 2001;13:S991.
63. Tjandra T, Brooks JC, Figueiredo P, Wise R, Matthews PM, Tracey I. Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design. Neuroimage 2005;27:393-401.
64. Luh WM, Wong EC, Bandettini PA, Ward BD, Hyde JS. Comparison of simultaneously measured perfusion and BOLD signal increases during brain activation with T(1)-based tissue identification. Magn Reson Med 2000;44:137-143.
65. Schulte AC, Speck O, Oesterle C, Hennig J. Separation and quantification of perfusion and BOLD effects by simultaneous acquisition of functional I(0)- and T2(*)-parameter maps. Magn Reson Med 2001;45:811-816.
66. Sicard KM, Duong TQ. Effects of hypoxia, hyperoxia, and hypercapnia on baseline and stimulus-evoked BOLD, CBF, and CMRO(2) in spontaneously breathing animals. Neuroimage 2005;25:850-858.
67. Luo F, Wu G, Li Z, Li SJ. Characterization of effects of mean arterial blood pressure induced by cocaine and cocaine methiodide on BOLD signals in rat brain. Magn Reson Med 2003;49:264-270.
68. Thiel CM, Henson RN, Morris JS, Friston KJ, Dolan RJ. Pharmacological modulation of behavioral and neuronal correlates of repetition priming. J Neurosci 2001;21:6846-6852.
69. Panerai RB, Simpson DM, Deverson ST, Mahony P, Hayes P, Evans DH. Multivariate dynamic analysis of cerebral blood flow regulation in humans. IEEE Trans Biomed Eng 2000;47:419-423.
70. Wise RG, Ide K, Poulin MJ, Tracey I. Resting fluctuations in arterial carbon dioxide induce significant low frequency variations in BOLD signal. Neuroimage 2004;21:1652-1664.
71. Leslie RA, James MF. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol Sci 2000;21:314-318.
72. Honey G, Bullmore E. Human pharmacological MRI. Trends Pharmacol Sci 2004;25:366-374.
73. Jones AK, Qi LY, Fujirawa T, et al. In vivo distribution of opioid receptors in man in relation to the cortical projections of the medial and lateral pain systems measured with positron emission tomography. Neurosci Lett 1991;126:25-28.
74. Bantick SJ, Wise RG, Ploghaus A, Clare S, Smith SM, Tracey I. Imaging how attention modulates pain in humans using functional MRI. Brain 2002;125:310-319.
75. Wilkinson D, Halligan P. The relevance of behavioural measures for functional-imaging studies of cognition. Nat Rev Neurosci 2004;5:67-73.
76. Wise RG, Williams P, Tracey I. Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain. Neuropsychopharmacology 2004;29:626-635.
77. Koeppe C, Schneider C, Thieme K, et al. The influence of the 5-HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study. Scand J Rheumatol Suppl 2004:24-27.
78. Arthurs OJ, Williams EJ, Carpenter TA, Pickard JD, Boniface SJ. Linear coupling between functional magnetic resonance imaging and evoked potential amplitude in human somatosensory cortex. Neuroscience 2000;101:803-806.
79. Arthurs OJ, Stephenson CM, Rice K, et al. Dopaminergic effects on electrophysiological and functional MRI measures of human cortical stimulus-response power laws. Neuroimage 2004;21:540-546.
80. Arthurs OJ, Johansen-Berg H, Matthews PM, Boniface SJ. Attention differentially modulates the coupling of fMRI BOLD and evoked potential signal amplitudes in the human somatosensory cortex. Exp Brain Res 2004;157:269-274.
81. Iannetti GD, Niazy RK, Wise RG, et al. Simultaneous recording of laser-evoked brain potentials and continuous, high-field functional magnetic resonance imaging in humans. Neuroimage 2005;28:708-719.
82. Lemieux L, Salek-Haddadi A, Josephs O, et al. Event-related fMRI with simultaneous and continuous EEG: description of the method and initial case report. Neuroimage 2001;14:780-787.
83. Buxton RB. An introduction to functional magnetic resonance imaging: principles and techniques. Cambridge: Cambridge University Press: 2002.
84. Pfeuffer J, Adriany G, Shmuel A, et al. Perfusion-based high-resolution functional imaging in the human brain at 7 Tesla. Magn Reson Med 2002;47:903-911.
85. Wang J, Aguirre GK, Kimberg DY, Detre JA. Empirical analyses of null-hypothesis perfusion FMRI data at 1.5 and 4 T. Neuroimage 2003;19:1449-1462.
86. Jahng GH, Song E, Zhu XP, Matson GB, Weiner MW, Schuff N. Human brain: reliability and reproducibility of pulsed arterial spin-labeling perfusion MR imaging. Radiology 2005;234:909-916.
87. Garraux G, Hallett M, Talagala SL. CASL fMRI of subcorticocortical perfusion changes during memory-guided finger sequences. Neuroimage 2005;25:122-132.
88. Talagala SL, Ye FQ, Ledden PJ, Chesnick S. Whole-brain 3D perfusion MRI at 3.0 T using CASL with a separate labeling coil. Magn Reson Med 2004;52:131-140.
89. Davis TL, Kwong KK, Weisskoff RM, Rosen BR. Calibrated functional MRI: mapping the dynamics of oxidative metabolism. Proc Natl Acad Sci USA 1998;95:1834-1839.
90. St Lawrence KS, Ye FQ, Lewis BK, Frank JA, McLaughlin AC. Measuring the effects of indomethacin on changes in cerebral oxidative metabolism and cerebral blood flow during sensorimotor activation. Magn Reson Med 2003;50:99-106.
91. Stroman PW, Kornelsen J, Lawrence J. An improved method for spinal functional MRI with large volume coverage of the spinal cord. J Magn Reson Imaging 2005;21:520-526.
92. Malisza KL, Stroman PW, Turner A, Gregorash L, Foniok T, Wright A. Functional MRI of the rat lumbar spinal cord involving painful stimulation and the effect of peripheral joint mobilization. J Magn Reson Imaging 2003;18:152-159.
93. Brooks J, Tracey I. From nociception to pain perception: imaging the spinal and supraspinal pathways. J Anat 2005;207:19-33.
94. Borsook D, Burstein R, Becerra L. Functional imaging of the human trigeminal system: opportunities for new insights into pain processing in health and disease. J Neurobiol 2004;61:107-125.
95. Borsook D, DaSilva AF, Ploghaus A, Becerra L. Specific and somatotopic functional magnetic resonance imaging activation in the trigeminal ganglion by brush and noxious heat. J Neurosci 2003;23:7897-7903.
96. DaSilva AF, Becerra L, Makris N, et al. Somatotopic activation in the human trigeminal pain pathway. J Neurosci 2002;22:8183-8192.
97. Hariri AR, Weinberger DR. Imaging genomics. Br Med Bull 2003;65:259-270.
98. Hariri AR, Weinberger DR. Functional neuroimaging of genetic variation in serotonergic neurotransmission. Genes Brain Behav 2003;2:341-349.
99. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003;299:1240-1243.
100. Sweeney BP. Do genes influence outcome from anaesthesia? Br J Anaesth 2003;90:725-727.
101. Mattay VS, Goldberg TE, Fera F, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003;100:6186-6191.